NEUREN PHARMACEUTICALS LIMITED - Announcements

5.76%

$13.10

Market Cap $1.629B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

MEMPHASYS LIMITED

Memphasys Ltd is a listed Australian MedTech company (ASX: MEM) focussed on reproductive biotechnology. Driven by market needs, Memphasys is developing a portfolio of device, diagnostic and media products that address human and animal reproduction issues.

Announcements

Filter Results

All Price Sensitive Only

NEU	Q1 2023 quarterly activity and cash flow report	PRICE SENSITIVE	28/04/23	331.52KB	Share
NEU	Appendix 4G		27/04/23	149.33KB	Share
NEU	2022 Annual Report to shareholders		27/04/23	1.81MB	Share
NEU	DAYBUE (trofinetide) launched in US - Neuren earns US$40m	PRICE SENSITIVE	18/04/23	330.95KB	Share
NEU	Application for quotation of securities - NEU		27/03/23	24.24KB	Share
NEU	Investor Presentation, 14 March 2023		14/03/23	1.49MB	Share
NEU	Notification of investor webinar		13/03/23	155.1KB	Share
NEU	FDA approves Daybue - the first treatment for Rett syndrome	PRICE SENSITIVE	13/03/23	258.83KB	Share
NEU	Initial Director's Interest Notice		02/03/23	170.86KB	Share
NEU	Neuren appoints Joe Basile to board of directors		02/03/23	120.39KB	Share
NEU	Investor presentation, 1 March 2023		01/03/23	1.54MB	Share
NEU	Investor Presentation, 24 February 2023		24/02/23	1.32MB	Share
NEU	Neuren reports 2022 full-year results	PRICE SENSITIVE	24/02/23	177.83KB	Share
NEU	Appendix 4E and 2022 full year accounts	PRICE SENSITIVE	24/02/23	458.57KB	Share
NEU	Application for quotation of securities - NEU		21/02/23	24.25KB	Share
NEU	Q4 2022 quarterly activity and cash flow report	PRICE SENSITIVE	31/01/23	278.86KB	Share
NEU	Prader-Willi syndrome IND for NNZ-2591 approved by FDA	PRICE SENSITIVE	23/01/23	149.69KB	Share
NEU	Neuren submits IND & first patients complete Phase 2 trials	PRICE SENSITIVE	23/12/22	285.67KB	Share
NEU	Becoming a substantial holder		07/12/22	197.83KB	Share
NEU	Ceasing to be a substantial holder		02/12/22	90.6KB	Share
NEU	Change in substantial holding		23/11/22	250.67KB	Share
NEU	Jefferies London Healthcare Conference 2022 presentation		18/11/22	1.25MB	Share
NEU	Q3 2022 quarterly activity and cash flow report	PRICE SENSITIVE	27/10/22	409.29KB	Share
NEU	Neuren receives US$10 million milestone payment	PRICE SENSITIVE	20/10/22	147.13KB	Share
NEU	Investor presentation, 14 September 2022		14/09/22	1.38MB	Share
NEU	Rett Syndrome NDA accepted for Priority Review by FDA	PRICE SENSITIVE	13/09/22	231.46KB	Share
NEU	S&P DJI Announces September 2022 Quarterly Rebalance	PRICE SENSITIVE	02/09/22	134KB	Share
NEU	Half-year shareholder update		24/08/22	283.08KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	24/08/22	338.87KB	Share
NEU	Investor presentation, 8 August 2022		08/08/22	1.18MB	Share
NEU	Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS	PRICE SENSITIVE	08/08/22	178.95KB	Share
NEU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	349.07KB	Share
NEU	Acadia submits Rett Syndrome New Drug Application to the FDA	PRICE SENSITIVE	19/07/22	309.46KB	Share
NEU	Neuren commences Phase 2 trial of NNZ-2591 in Angelman	PRICE SENSITIVE	12/07/22	154.47KB	Share
NEU	Notification regarding unquoted securities - NEU		08/07/22	27.75KB	Share
NEU	Neuren appoints Chief Medical Officer in United States	PRICE SENSITIVE	08/07/22	150.09KB	Share
NEU	Results of Meeting		30/05/22	63.57KB	Share
NEU	AGM Chairman's Address & CEO Presentation		30/05/22	683.09KB	Share
NEU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	276.23KB	Share
NEU	Virtual AGM online guide		28/04/22	1MB	Share
NEU	Notice of Annual General Meeting/Proxy Form		28/04/22	781.61KB	Share
NEU	Change in substantial holding		27/04/22	235.82KB	Share
NEU	Appendix 4G		27/04/22	146.25KB	Share
NEU	Annual Report to shareholders		27/04/22	1.72MB	Share
NEU	FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial	PRICE SENSITIVE	25/03/22	151.55KB	Share
NEU	FDA approval for Phelan-McDermid IND and Phase 2 trial	PRICE SENSITIVE	23/03/22	152.68KB	Share
NEU	Ethics approval for Angelman Phase 2 trial in Australia	PRICE SENSITIVE	11/03/22	152.94KB	Share
NEU	S&P DJI Announces March 2022 Quarterly Rebalance	PRICE SENSITIVE	04/03/22	175.5KB	Share
NEU	Investor presentation 25 Feb 2022		25/02/22	886.27KB	Share
NEU	FDA approval for Angelman IND and Phase 2 trial	PRICE SENSITIVE	25/02/22	154.3KB	Share
NEU	2021 Results - a transformational year for Neuren	PRICE SENSITIVE	24/02/22	175.8KB	Share
NEU	Preliminary Final Report and 2021 Full Year Accounts	PRICE SENSITIVE	24/02/22	486.79KB	Share
NEU	Notification regarding unquoted securities - NEU		03/02/22	28.31KB	Share
NEU	Neuren appoints Vice President, Corporate Development		01/02/22	147.8KB	Share
NEU	Q4 2021 quarterly activity and cash flow report	PRICE SENSITIVE	31/01/22	339.96KB	Share
NEU	Becoming a substantial holder		10/12/21	200.6KB	Share
NEU	Positive topline results from Phase 3 trial in Rett syndrome	PRICE SENSITIVE	07/12/21	174.6KB	Share
NEU	Neuren presenting at Bell Potter Healthcare Conference		10/11/21	719.92KB	Share
NEU	Q3 2021 quarterly activity and cash flow report	PRICE SENSITIVE	28/10/21	274.92KB	Share
NEU	Neuren receives feedback on IND for Phelan-McDermid syndrome	PRICE SENSITIVE	21/10/21	148.11KB	Share
NEU	Change of Director's Interest Notice - D Angus		20/10/21	70.8KB	Share
NEU	US patent to 2034 granted for Neuren's NNZ-2591 in autism	PRICE SENSITIVE	11/10/21	148.04KB	Share
NEU	Change of Director's Interest Notice - J Harry		08/10/21	96.15KB	Share
NEU	Change of Director's Interest Notice - J Pilcher		08/10/21	96.53KB	Share
NEU	Change of Director's Interest Notice - P Davies		08/10/21	96.24KB	Share
NEU	Application for quotation of securities - NEU		08/10/21	24.45KB	Share
NEU	Update - Proposed issue of securities - NEU		06/10/21	35.14KB	Share
NEU	$3.3 million raised from oversubscribed SPP	PRICE SENSITIVE	06/10/21	125.58KB	Share
NEU	Feedback on Angelman IND and submission of Pitt Hopkins IND	PRICE SENSITIVE	01/10/21	149.68KB	Share
NEU	IND application submitted for NNZ-2591 in Phelan-McDermid	PRICE SENSITIVE	21/09/21	150.63KB	Share
NEU	Share Purchase Plan Offer Booklet	PRICE SENSITIVE	17/09/21	219.19KB	Share
NEU	Section 708A Notice		16/09/21	278.17KB	Share
NEU	New patent issued to 2032 for Neuren's trofinetide in Brazil	PRICE SENSITIVE	16/09/21	154.69KB	Share
NEU	Application for quotation of securities - NEU		16/09/21	24.77KB	Share
NEU	Investor Presentation, 13 September 2021	PRICE SENSITIVE	13/09/21	1.66MB	Share
NEU	Proposed issue of securities - NEU	PRICE SENSITIVE	13/09/21	35.17KB	Share
NEU	Placement to accelerate NNZ-2591 across 4 indications	PRICE SENSITIVE	13/09/21	177.69KB	Share
NEU	Notification of investor presentation, 9.00 AEST 13 Sept 21		10/09/21	122.77KB	Share
NEU	Trading Halt	PRICE SENSITIVE	09/09/21	193.13KB	Share
NEU	FDA grants Orphan Drug designation for Prader-Willi syndrome	PRICE SENSITIVE	03/09/21	152.03KB	Share
NEU	Angelman IND and Ethics applications submitted for NNZ-2591	PRICE SENSITIVE	01/09/21	149.97KB	Share
NEU	Trofinetide Rett syndrome clinical trial in girls aged 2-5		01/09/21	174.1KB	Share
NEU	R&D Tax Incentive Advance Overseas Finding Approval	PRICE SENSITIVE	30/08/21	150.81KB	Share
NEU	Half-year shareholder update		25/08/21	199.96KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	25/08/21	345.88KB	Share
NEU	Notification of investor webinar		17/08/21	146.14KB	Share
NEU	Phase 3 enrolment successfully completed, results in Q4 2021	PRICE SENSITIVE	05/08/21	214.02KB	Share
NEU	Q2 2021 quarterly activity and cash flow report	PRICE SENSITIVE	30/07/21	323.96KB	Share
NEU	Change of Director's Interest Notice		28/06/21	71.22KB	Share
NEU	Results of Meeting		22/06/21	61.72KB	Share
NEU	AGM Chairman's Address and CEO Presentation		22/06/21	731.5KB	Share
NEU	Change of Director's Interest Notice		16/06/21	96.53KB	Share
NEU	Investor presentation, 15 June 2021		15/06/21	859.76KB	Share
NEU	Initial Director's Interest Notice		15/06/21	64.56KB	Share
NEU	Neuren CEO Jon Pilcher appointed to board of directors		15/06/21	146.32KB	Share
NEU	Neuren to present at MST Access investor conference		10/06/21	145.33KB	Share
NEU	Update - Annual General Meeting 2021		10/06/21	147.49KB	Share
NEU	Positive FDA meetings enable INDs for three Phase 2 trials	PRICE SENSITIVE	01/06/21	150.7KB	Share
NEU	Virtual AGM online guide		21/05/21	1.7MB	Share
NEU	Notice of Annual General Meeting/Proxy Form		21/05/21	317.22KB	Share

NEU Q1 2023 quarterly activity and cash flow report
28/04/23	PRICE SENSITIVE	331.52KB	Share
NEU Appendix 4G
27/04/23		149.33KB	Share
NEU 2022 Annual Report to shareholders
27/04/23		1.81MB	Share
NEU DAYBUE (trofinetide) launched in US - Neuren earns US$40m
18/04/23	PRICE SENSITIVE	330.95KB	Share
NEU Application for quotation of securities - NEU
27/03/23		24.24KB	Share
NEU Investor Presentation, 14 March 2023
14/03/23		1.49MB	Share
NEU Notification of investor webinar
13/03/23		155.1KB	Share
NEU FDA approves Daybue - the first treatment for Rett syndrome
13/03/23	PRICE SENSITIVE	258.83KB	Share
NEU Initial Director's Interest Notice
02/03/23		170.86KB	Share
NEU Neuren appoints Joe Basile to board of directors
02/03/23		120.39KB	Share
NEU Investor presentation, 1 March 2023
01/03/23		1.54MB	Share
NEU Investor Presentation, 24 February 2023
24/02/23		1.32MB	Share
NEU Neuren reports 2022 full-year results
24/02/23	PRICE SENSITIVE	177.83KB	Share
NEU Appendix 4E and 2022 full year accounts
24/02/23	PRICE SENSITIVE	458.57KB	Share
NEU Application for quotation of securities - NEU
21/02/23		24.25KB	Share
NEU Q4 2022 quarterly activity and cash flow report
31/01/23	PRICE SENSITIVE	278.86KB	Share
NEU Prader-Willi syndrome IND for NNZ-2591 approved by FDA
23/01/23	PRICE SENSITIVE	149.69KB	Share
NEU Neuren submits IND & first patients complete Phase 2 trials
23/12/22	PRICE SENSITIVE	285.67KB	Share
NEU Becoming a substantial holder
07/12/22		197.83KB	Share
NEU Ceasing to be a substantial holder
02/12/22		90.6KB	Share
NEU Change in substantial holding
23/11/22		250.67KB	Share
NEU Jefferies London Healthcare Conference 2022 presentation
18/11/22		1.25MB	Share
NEU Q3 2022 quarterly activity and cash flow report
27/10/22	PRICE SENSITIVE	409.29KB	Share
NEU Neuren receives US$10 million milestone payment
20/10/22	PRICE SENSITIVE	147.13KB	Share
NEU Investor presentation, 14 September 2022
14/09/22		1.38MB	Share
NEU Rett Syndrome NDA accepted for Priority Review by FDA
13/09/22	PRICE SENSITIVE	231.46KB	Share
NEU S&P DJI Announces September 2022 Quarterly Rebalance
02/09/22	PRICE SENSITIVE	134KB	Share
NEU Half-year shareholder update
24/08/22		283.08KB	Share
NEU Half Yearly Report and Accounts
24/08/22	PRICE SENSITIVE	338.87KB	Share
NEU Investor presentation, 8 August 2022
08/08/22		1.18MB	Share
NEU Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
08/08/22	PRICE SENSITIVE	178.95KB	Share
NEU Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	349.07KB	Share
NEU Acadia submits Rett Syndrome New Drug Application to the FDA
19/07/22	PRICE SENSITIVE	309.46KB	Share
NEU Neuren commences Phase 2 trial of NNZ-2591 in Angelman
12/07/22	PRICE SENSITIVE	154.47KB	Share
NEU Notification regarding unquoted securities - NEU
08/07/22		27.75KB	Share
NEU Neuren appoints Chief Medical Officer in United States
08/07/22	PRICE SENSITIVE	150.09KB	Share
NEU Results of Meeting
30/05/22		63.57KB	Share
NEU AGM Chairman's Address & CEO Presentation
30/05/22		683.09KB	Share
NEU Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	276.23KB	Share
NEU Virtual AGM online guide
28/04/22		1MB	Share
NEU Notice of Annual General Meeting/Proxy Form
28/04/22		781.61KB	Share
NEU Change in substantial holding
27/04/22		235.82KB	Share
NEU Appendix 4G
27/04/22		146.25KB	Share
NEU Annual Report to shareholders
27/04/22		1.72MB	Share
NEU FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
25/03/22	PRICE SENSITIVE	151.55KB	Share
NEU FDA approval for Phelan-McDermid IND and Phase 2 trial
23/03/22	PRICE SENSITIVE	152.68KB	Share
NEU Ethics approval for Angelman Phase 2 trial in Australia
11/03/22	PRICE SENSITIVE	152.94KB	Share
NEU S&P DJI Announces March 2022 Quarterly Rebalance
04/03/22	PRICE SENSITIVE	175.5KB	Share
NEU Investor presentation 25 Feb 2022
25/02/22		886.27KB	Share
NEU FDA approval for Angelman IND and Phase 2 trial
25/02/22	PRICE SENSITIVE	154.3KB	Share
NEU 2021 Results - a transformational year for Neuren
24/02/22	PRICE SENSITIVE	175.8KB	Share
NEU Preliminary Final Report and 2021 Full Year Accounts
24/02/22	PRICE SENSITIVE	486.79KB	Share
NEU Notification regarding unquoted securities - NEU
03/02/22		28.31KB	Share
NEU Neuren appoints Vice President, Corporate Development
01/02/22		147.8KB	Share
NEU Q4 2021 quarterly activity and cash flow report
31/01/22	PRICE SENSITIVE	339.96KB	Share
NEU Becoming a substantial holder
10/12/21		200.6KB	Share
NEU Positive topline results from Phase 3 trial in Rett syndrome
07/12/21	PRICE SENSITIVE	174.6KB	Share
NEU Neuren presenting at Bell Potter Healthcare Conference
10/11/21		719.92KB	Share
NEU Q3 2021 quarterly activity and cash flow report
28/10/21	PRICE SENSITIVE	274.92KB	Share
NEU Neuren receives feedback on IND for Phelan-McDermid syndrome
21/10/21	PRICE SENSITIVE	148.11KB	Share
NEU Change of Director's Interest Notice - D Angus
20/10/21		70.8KB	Share
NEU US patent to 2034 granted for Neuren's NNZ-2591 in autism
11/10/21	PRICE SENSITIVE	148.04KB	Share
NEU Change of Director's Interest Notice - J Harry
08/10/21		96.15KB	Share
NEU Change of Director's Interest Notice - J Pilcher
08/10/21		96.53KB	Share
NEU Change of Director's Interest Notice - P Davies
08/10/21		96.24KB	Share
NEU Application for quotation of securities - NEU
08/10/21		24.45KB	Share
NEU Update - Proposed issue of securities - NEU
06/10/21		35.14KB	Share
NEU $3.3 million raised from oversubscribed SPP
06/10/21	PRICE SENSITIVE	125.58KB	Share
NEU Feedback on Angelman IND and submission of Pitt Hopkins IND
01/10/21	PRICE SENSITIVE	149.68KB	Share
NEU IND application submitted for NNZ-2591 in Phelan-McDermid
21/09/21	PRICE SENSITIVE	150.63KB	Share
NEU Share Purchase Plan Offer Booklet
17/09/21	PRICE SENSITIVE	219.19KB	Share
NEU Section 708A Notice
16/09/21		278.17KB	Share
NEU New patent issued to 2032 for Neuren's trofinetide in Brazil
16/09/21	PRICE SENSITIVE	154.69KB	Share
NEU Application for quotation of securities - NEU
16/09/21		24.77KB	Share
NEU Investor Presentation, 13 September 2021
13/09/21	PRICE SENSITIVE	1.66MB	Share
NEU Proposed issue of securities - NEU
13/09/21	PRICE SENSITIVE	35.17KB	Share
NEU Placement to accelerate NNZ-2591 across 4 indications
13/09/21	PRICE SENSITIVE	177.69KB	Share
NEU Notification of investor presentation, 9.00 AEST 13 Sept 21
10/09/21		122.77KB	Share
NEU Trading Halt
09/09/21	PRICE SENSITIVE	193.13KB	Share
NEU FDA grants Orphan Drug designation for Prader-Willi syndrome
03/09/21	PRICE SENSITIVE	152.03KB	Share
NEU Angelman IND and Ethics applications submitted for NNZ-2591
01/09/21	PRICE SENSITIVE	149.97KB	Share
NEU Trofinetide Rett syndrome clinical trial in girls aged 2-5
01/09/21		174.1KB	Share
NEU R&D Tax Incentive Advance Overseas Finding Approval
30/08/21	PRICE SENSITIVE	150.81KB	Share
NEU Half-year shareholder update
25/08/21		199.96KB	Share
NEU Half Yearly Report and Accounts
25/08/21	PRICE SENSITIVE	345.88KB	Share
NEU Notification of investor webinar
17/08/21		146.14KB	Share
NEU Phase 3 enrolment successfully completed, results in Q4 2021
05/08/21	PRICE SENSITIVE	214.02KB	Share
NEU Q2 2021 quarterly activity and cash flow report
30/07/21	PRICE SENSITIVE	323.96KB	Share
NEU Change of Director's Interest Notice
28/06/21		71.22KB	Share
NEU Results of Meeting
22/06/21		61.72KB	Share
NEU AGM Chairman's Address and CEO Presentation
22/06/21		731.5KB	Share
NEU Change of Director's Interest Notice
16/06/21		96.53KB	Share
NEU Investor presentation, 15 June 2021
15/06/21		859.76KB	Share
NEU Initial Director's Interest Notice
15/06/21		64.56KB	Share
NEU Neuren CEO Jon Pilcher appointed to board of directors
15/06/21		146.32KB	Share
NEU Neuren to present at MST Access investor conference
10/06/21		145.33KB	Share
NEU Update - Annual General Meeting 2021
10/06/21		147.49KB	Share
NEU Positive FDA meetings enable INDs for three Phase 2 trials
01/06/21	PRICE SENSITIVE	150.7KB	Share
NEU Virtual AGM online guide
21/05/21		1.7MB	Share
NEU Notice of Annual General Meeting/Proxy Form
21/05/21		317.22KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.10		Change -0.800(5.76%)		Mkt cap ! $1.629B

Open	High	Low	Value	Volume
$13.95	$13.96	$12.88	$9.534M	725.6K

Buyers (Bids)

No.	Vol.	Price($)
1	266	$13.10

Sellers (Offers)

Price($)	Vol.	No.
$13.15	1619	2

View Market Depth

No.	Vol.	Price($)
1	667	13.080
2	154	13.000
1	77	12.930
1	39	12.920
1	21	12.900

Price($)	Vol.	No.
13.190	1305	1
13.560	2250	1
13.880	748	1
14.000	60	1
14.020	10000	1

Last trade - 16.10pm 13/06/2025 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories